Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(60.0%)
N/A
1(20.0%)
Phase 1
1(20.0%)
5Total
Phase 2(3)
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06382909Not ApplicableCompleted

Effect of Probiotic Compound K11T e K11TMax in ASD

Role: collaborator

NCT05671796Phase 2Unknown

Autologous Bone Marrow Stem Cell Transplantation in Patients With Subacute Spinal Cord Injury

Role: lead

NCT05542693Phase 2Unknown

Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine

Role: collaborator

NCT05446961Phase 2Completed

Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus

Role: lead

NCT04844268Phase 1Unknown

Study to Assess Safety, Reactogenicity and Immunogenicity of the VACCINE RNA MCTI CIMATEC HDT (HDT-301) Vaccine Against COVID-19

Role: lead

All 5 trials loaded